Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by unclepiemanon Sep 02, 2018 2:24pm
105 Views
Post# 28554554

RE:RE:RE:RE:Vaccinex is now public

RE:RE:RE:RE:Vaccinex is now publicProblem looks to be that BTI lacked ability (and perhaps even now) to negotiate real terms. Most companies out there with ground breaking tech don't just lay there letting other pharma do as they please. 

How in the world did we do ANY licensing test deals with these pharms without putting in stipulations for anouncements, milestones, and deadline on a decision to advance to next step or not?

just wow, and don't tell me "this is normal" because IT IS NOT. It's not 1992. Go search most pharma deals, they all have speicfics called out in their deals to protect share holders from being walked over and pps dropping to near zero.

We are either not getting any new deals which is why the new BTI mgmt has not provided details of better negotiated partnership trials OR the new mgmt is just as bad as the old mgmt when it comes to protecting shareholder interest and making deals.
Bullboard Posts